21
ALL1
PANTHERx Rare Pharmacy20
PharmingYear
21
ALL1
20253
20249
20237
20221
2020DEALS // DEV.
21
ALL1
Deals20
DevelopmentsCountry
21
ALL20
NETHERLANDS1
U.S.A21
ALL18
Inapplicable3
Novartis Pharmaceuticals CorporationTherapeutic Area
21
ALL2
Genetic Disease1
Immunology18
Rare Diseases and DisordersStudy Phase
21
ALL17
Approved FDF1
Phase III1
Phase II/ Phase III2
Phase IIDeal Type
21
ALL1
Divestment20
InapplicableProduct Type
21
ALL21
Other Small MoleculeDosage Form
21
ALL20
Oral Capsule1
Oral Tablet, Film CoatedLead Product
21
ALL21
Leniolisib PhosphateTarget
21
ALL21
PI3K-deltaLead Product(s) : Leniolisib Phosphate
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Group Begins Phase II Leniolisib Trial for CVID Treatment
Details : Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of common variable immunodeficiency (CVID) with immune dysregulation.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Announces Positive Topline Data in Pediatric Clinical Trial of Leniolisib
Details : Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Begins Phase II Trial of Leniolisib in Primary Immunodeficiencies
Details : Joenja (leniolisib) is an oral small molecule PI3K delta inhibitor, which is currently being evaluated for the treatment of primary immunodeficiency disorders.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Details : Joenja (leniolisib) is an oral PI3K delta inhibitor, the first targeted treatment for activated PI3K delta syndrome in patients aged 12 and older, now being developed for children aged 4 to 11.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral small molecule PI3Kẟ inhibitor approved in US as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Leniolisib is an oral small molecule phosphoinositide 3-kinase delta inhibitor approved in the US as the first and only targeted treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older.
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PANTHERx® Rare Launches Drug for APDS
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Joenja (leniolisib) is an oral, selective PI3K-delta inhibitor which inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and to the dysregulation of B and T cells in patients with ...
Product Name : Joenja
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2023
Lead Product(s) : Leniolisib Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable